NCP@pyrolipid combines two therapeutic modalities, chemotherapy and PDT, to elicit antitumor immunity [272], as evidenced by early calreticulin (CRT) exposure on the cell surface, antitumor vaccination, tumor-specific T-cell response, and an abscopal effect. Here, CALR is linked to neoplasm.